Cancer Research

Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics

06/29/2026

Collaboration combines Voro’s tumor-activated biologics platform and T-cell engager (TCE) expertise with Alloy’s antibody discovery and TCE engineering capabilities to develop novel tumor-selective immunotherapies Excerpt from the Press Release: SAN DIEGO & BOSTON–(BUSINESS WIRE)–Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies, and Alloy Therapeutics, a biotechnology…

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

06/23/2026

Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Excerpt from the Press Release: CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer…

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

06/22/2026

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x’s single cell and spatial platforms Excerpt from the Press Release: PLEASANTON, Calif., June 17, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland…

Prolocor Announces Results of NIH-funded Study Demonstrating That Platelet FcγRIIa Identifies Cancer Patients at Increased Risk of Death and Thrombotic Events

05/27/2026

Excerpt from the Press Release: PHILADELPHIA, PA / ACCESS Newswire / May 20, 2026 / Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, announced the publication of a recently completed study entitled Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death…

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

05/22/2026

First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC Excerpt from the Press Release: SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Sapu Nano today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, the…

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

05/21/2026

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after –  – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical trials –  – All active patients in the treatment arm have reached their second DURAVYU dosing visit, with over 35% receiving…

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

05/19/2026

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results SID data…

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

05/18/2026

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company anticipates providing updates in 2H 2026 as enrollment progresses through dose escalation cohorts Excerpt from the Press Release:…

Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

05/13/2026

Excerpt from the Press Release: TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global, multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a key…

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

05/12/2026

200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen Excerpt from the Press Release: PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today…